Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tivicay

- PMLiVE

ViiV Healthcare receives NICE recommendation for HIV prevention therapy

The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

- PMLiVE

Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

An estimated 1.2 million people in the US are currently living with the virus

- PMLiVE

Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

More than 100 people in the US were diagnosed with HIV every day in 2023

- PMLiVE

Cultivating Interest in Infectious Disease Education at ID Week 2024

IDWeek starts tomorrow, October 16, and Medscape is bringing outcomes and education! We are excited to announce Medscape is presenting six posters that highlight the significant impact of our educational...

Medscape Education

- PMLiVE

GSK’s ViiV shares positive head-to-head results for two-drug HIV regimen Dovato

The phase 4 trial has been comparing Dovato against Gilead’s three-drug regimen, Biktarvy

- PMLiVE

Reaching Women Where They’re At: Setting Up a Safe Space for HIV Prevention Conversations

“I always enjoyed solving problems and putting puzzles together,” says Harmony Garges, MD, CMO at ViiV Healthcare and a pediatric infectious disease specialist. “So for me, infectious disease was a...

Medscape Education

- PMLiVE

World AIDS Day 35: Medscape’s Commitment to the Elimination of HIV through Education and Looking Towards the Future

December 1 marks the 35th year commemorating World AIDS Day, and the theme is “Remember and Commit.” While new infections have steadily declined over the last several years, HIV remains a...

Medscape Education

Article: Could combating stigma increase the uptake of PrEP and finally end the HIV epidemic?

In this article we explore what more could be done by the pharmaceutical industry to help prevent the spread of HIV infection worldwide.

Inizio

- PMLiVE

WHO calls for leaders to address the global HIV response

Its key focus is to highlight inequalities that hinder progress in the goal to end AIDS by 2030

- PMLiVE

GSK’s ViiV submits application for cabotegravir to EMA for HIV-1 prevention

Cabotegravir offers up to two months of protection from a single injection

- PMLiVE

Gilead’s latest Biktarvy data offers hope to HIV patients

The data was shared at the 30th International Congress on Drug Therapy in HIV Infection

- PMLiVE

NHS England launches hepatitis C screening scheme to reach 2030 elimination goal

The new scheme could help diagnose up to 80,000 people who do not know they have hepatitis C

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links